Novel Treatment Pathways in Pulmonary Arterial Hypertension

Kanza N. Qaiser; Adriano R. Tonelli

doi:10.14797/CBHS2234

Novel Treatment Pathways in Pulmonary Arterial Hypertension

Methodist DeBakey Cardiovascular Journal

Volume 17 (2021): Issue 2

By: Kanza N. Qaiser and Adriano R. Tonelli

Open Access

|Jul 2021

Abstract

Pulmonary arterial hypertension (PAH) is a severe and progressive vascular disease characterized by pulmonary vascular remodeling, proliferation, and inflammation. Despite the availability of effective treatments, PAH may culminate in right ventricular failure and death. Currently approved medications act through three well-characterized pathways: the nitric oxide, endothelin, and prostacyclin pathways. Ongoing research efforts continue to expand our understanding of the molecular pathogenesis of this complex and multifactorial disease. Based on recent discoveries in the pathobiology of PAH, several new treatments are being developed and tested with the goal of modifying the disease process and ultimately improving the long-term prognosis.

References

Galie N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J. 2010 Sep; 31(17): 2080–6. doi: 10.1093/eurheartj/ehq152.
Search in Google Scholar Back to article
Tonelli AR, Arelli V, Minai OA, et al. Causes and circumstances of death in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013 Aug 1; 188(3): 365–9. doi: 10.1164/rccm.201209-1640OC. 2013; 188: 365–9.
Search in Google Scholar Back to article
Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012 Aug; 142(2): 448–456. doi: 10.1378/chest.11-1460.
Search in Google Scholar Back to article
Hemnes AR, Humbert M. Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled. Eur Respir Rev. 2017 Dec 20; 26(146): 170093. doi: 10.1183/16000617.0093-2017.
Search in Google Scholar Back to article
Humbert M, Lau EM, Montani D, Jais X, Sitbon O, Simonneau G. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation. 2014 Dec 9; 130(24): 2189–208. doi: 10.1161/CIRCULATIONAHA.114.006974.
Search in Google Scholar Back to article
Zolty R. Pulmonary arterial hypertension specific therapy: The old and the new. Pharmacol Ther. 2020 Oct; 214: 107576. doi: 10.1016/j.pharmthera.2020.107576.
Search in Google Scholar Back to article
Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018 Mar 14; 360: j5492. doi: 10.1136/bmj.j5492.
Open DOI Search in Google Scholar Back to article
Tonelli AR, Alnuaimat H, Mubarak K. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respir Med. 2010 Apr; 104(4): 481–96. doi: 10.1016/j.rmed.2009.11.015.
Search in Google Scholar Back to article
Tonelli AR, Haserodt S, Aytekin M, Dweik RA. Nitric oxide deficiency in pulmonary hypertension: Pathobiology and implications for therapy. Pulm Circ. 2013 Jan; 3(1): 20–30. doi: 10.4103/2045-8932.109911.
Search in Google Scholar Back to article
Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999 Jun; 159(6): 1925–32. doi: 10.1164/ajrccm.159.6.9804054.
Search in Google Scholar Back to article
Falcetti E, Hall SM, Phillips PG, et al. Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010 Nov 1; 182(9): 1161–70. doi: 10.1164/rccm.201001-0011OC.
Search in Google Scholar Back to article
Tonelli AR, Zein J, Ioannidis JP. Geometry of the randomized evidence for treatments of pulmonary hypertension. Cardiovasc Ther. 2013 Dec; 31(6): e138–46. doi: 10.1111/1755-5922.12050.
Search in Google Scholar Back to article
Galie N, Barbera JA, Frost AE, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015; 373: 834–44. 2015 Aug 27; 373(9): 834–44. doi: 10.1056/NEJMoa1413687.
Search in Google Scholar Back to article
Ghofrani HA, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013 Jul 25; 369(4): 330–40. doi: 10.1056/NEJMoa1209655.
Search in Google Scholar Back to article
Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013 Aug 29; 369(9): 809–18. doi: 10.1056/NEJMoa1213917.
Search in Google Scholar Back to article
Sitbon O, Channick R, Chin KM, et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015 Dec 24; 373(26): 2522–33. doi: 10.1056/NEJMoa1503184.
Search in Google Scholar Back to article
Galie N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019 Jan 24; 53(1): 1801889. doi: 10.1183/13993003.01889-2018.
Search in Google Scholar Back to article
Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016 Jan 1; 37(1): 67–119. doi: 10.1093/eurheartj/ehv317.
Search in Google Scholar Back to article
Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. Chest. 2019 Aug; 156(2): 323–337. doi: 10.1016/j.chest.2019.02.004.
Search in Google Scholar Back to article
Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017 Aug 3; 50(2): 1700740. doi: 10.1183/13993003.00740-2017.
Search in Google Scholar Back to article
Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017 Aug 3; 50(2): 1700889. doi: 10.1183/13993003.00889-2017.
Search in Google Scholar Back to article
Macchia A, Marchioli R, Tognoni G, et al. Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am Heart J. 2010 Feb; 159(2): 245–57. doi: 10.1016/j.ahj.2009.11.028.
Search in Google Scholar Back to article
Lajoie AC, Lauziere G, Lega JC, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016 Apr; 4(4): 291–305. doi: 10.1016/S2213-2600(16)00027-8.
Search in Google Scholar Back to article
Chin KM, Sitbon O, Doelberg M, et al. Efficacy and safety of initial triple oral versus initial double oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension (PAH): results of the randomized controlled TRITON study. Am J Respir Crit Car Med. 2020; 201: A2928.
Search in Google Scholar Back to article
ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; c2021. Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy (REPLACE); 2021 Feb 26 [cited 2021 Apr 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT02891850.
Search in Google Scholar Back to article
Hoeper MM, Ghofrani HA, Al-Hiti H, et al. Late Breaking Abstract – Switching from PDE5i to riociguat in patients with PAH: The REPLACE study. Eur Resp J. 2020; 56: A3802.
Search in Google Scholar Back to article
ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; c2021. Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension (UNISUS); 2020 Feb 18 [cited 2021 Apr 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT04273945.
Search in Google Scholar Back to article
ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; c2021. A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension; 2020 Aug 7 [cited 2021 Apr 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT04503733.
Search in Google Scholar Back to article
Zhang C, Wang X, Zhang H, et al. Therapeutic Monoclonal Antibody Antagonizing Endothelin Receptor A for Pulmonary Arterial Hypertension. J Pharmacol Exp Ther. 2019 Jul; 370(1): 54–61. doi: 10.1124/jpet.118.252700.
Search in Google Scholar Back to article
Torres F, Farber H, Ristic A, et al. Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. Eur Respir J. 2019 Oct 10; 54(4): 1901030. doi: 10.1183/13993003.01030-2019.
Search in Google Scholar Back to article
ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; c2021. A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients; 2018 Aug 13 [cited 2021 Apr 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03626688.
Search in Google Scholar Back to article
ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; c2021. A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH (CAPACITY); 2019 Sep 10 [cited 2021 Apr 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT04084678.
Search in Google Scholar Back to article
Klose H, Chin KM, Ewert R, et al. Safety, Tolerability and Pharmacokinetics Study in Patients with Pulmonary Arterial Hypertension (PAH) Temporarily Switching from Oral to IV Selexipag. J Heart Lung Transplant. 2019 Apr 1; 38(4): S490. DOI: 10.1016/j.healun.2019.01.1247.
Search in Google Scholar Back to article
United Therapeutics [Internet]. Silver Spring, MD: United Therapeutics Corp.; c2021. United Therapeutics and DEKA Announce Additional FDA Clearance Related to the Unity Subcutaneous Delivery System for Remodulin®; 2020 Feb 24 [cited 2021 Apr 12]. Available from: https://ir.unither.com/news/press-releases/press-release-details/2020/United-Therapeutics-and-DEKA-Announce-Additional-FDA-Clearance-Related-to-the-Unity-Subcutaneous-Delivery-System-for-Remodulin/default.aspx.
Search in Google Scholar Back to article
Bourge RC, Waxman AB, Gomberg-Maitland M, et al. Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System: Results of the DelIVery for PAH Trial. Chest. 2016 Jul; 150(1): 27–34. doi: 10.1016/j.chest.2015.11.005.
Search in Google Scholar Back to article
Feldman J, Habib N, Fann J, Radosevich JJ. Treprostinil in the treatment of pulmonary arterial hypertension. Future Cardiol. 2020 Nov; 16(6): 547–558. doi: 10.2217/fca-2020-0021.
Search in Google Scholar Back to article
Shapiro S, Bourge RC, Pozella P, Harris DF, Borg EH, Nelsen AC. Implantable system for treprostinil: a real-world patient experience study. Pulm Circ. 2020 Apr 22; 10(2): 2045894020907881. doi: 10.1177/2045894020907881.
Search in Google Scholar Back to article
Orriols M, Gomez-Puerto MC, Ten Dijke P. BMP type II receptor as a therapeutic target in pulmonary arterial hypertension. Cell Mol Life Sci. 2017 Aug; 74(16): 2979–2995. doi: 10.1007/s00018-017-2510-4.
Search in Google Scholar Back to article
Fessel JP, Loyd JE, Austin ED. The genetics of pulmonary arterial hypertension in the post-BMPR2 era. Pulm Circ. Jul-Sep 2011; 1(3): 305–19. doi: 10.4103/2045-8932.87293.
Search in Google Scholar Back to article
Larkin EK, Newman JH, Austin ED, et al. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012 Nov 1; 186(9): 892–6. doi: 10.1164/rccm.201205-0886OC.
Search in Google Scholar Back to article
Atkinson C, Stewart S, Upton PD, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation. 2002 Apr 9; 105(14): 1672–8. doi: 10.1161/01.cir.0000012754.72951.3d.
Search in Google Scholar Back to article
Badesch D, Gibbs S, Gomberg-Maitland M, et al. PULSAR: A phase 2, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of sotatercept (ACE-011) when added to standard of care (SOC) for treatment of pulmonary arterial hypertension (PAH). Eur Respir J. 2019; 54(63): PA4750. doi: 10.1183/13993003.congress-2019.PA4750.
Search in Google Scholar Back to article
Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996 Feb 1; 334(5): 296–301. doi: 10.1056/NEJM199602013340504.
Search in Google Scholar Back to article
Perros F, Montani D, Dorfmuller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008 Jul 1; 178(1): 81–8. doi: 10.1164/rccm.200707-1037OC.
Search in Google Scholar Back to article
ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; c2021. Imatinib (QTI571) in Pulmonary Arterial Hypertension (IMPRES); 2009 May 15 [cited 2021 Apr 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT00902174.
Search in Google Scholar Back to article
Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013 Mar 12; 127(10): 1128–38. doi: 10.1161/CIRCULATIONAHA.112.000765.
Search in Google Scholar Back to article
Pitsiou G, Zarogoulidis P, Petridis D, et al. Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment. Drug Des Devel Ther. 2014 Oct 7; 8: 1753–63. doi: 10.2147/DDDT.S70277.
Open DOI Search in Google Scholar Back to article
Galkin A, Clemons B, Garcia E, et al. Abstract 11102: Gb002, A Novel Inhaled PDGFR Kinase Inhibitor, Demonstrates Efficacy in the Su5416 Hypoxia Rat Model of Pulmonary Arterial Hypertension (PAH). Circulation. 2019; 140(Suppl 1): A11102.
Search in Google Scholar Back to article
ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; c2021. Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension (PAH); 2019 Apr 25 15 [cited 2021 Apr 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03926793.
Search in Google Scholar Back to article
ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; c2021. GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH); 2020 Jul 7 [cited 2021 Apr 12]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04456998.
Search in Google Scholar Back to article
Chan SY, Rubin LJ. Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice. Eur Respir Rev. 2017 Dec 20; 26(146): 170094. doi: 10.1183/16000617.0094-2017.
Search in Google Scholar Back to article
ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; c2021. Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) – LARIAT; 2014 Jan 15 [cited 2021 Apr 12]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02036970.
Search in Google Scholar Back to article
Zhai C, Shi W, Feng W, et al. Activation of AMPK prevents monocrotaline-induced pulmonary arterial hypertension by suppression of NF-κB-mediated autophagy activation. Life Sci. 2018 Sep 1; 208: 87–95. doi: 10.1016/j.lfs.2018.07.018.
Search in Google Scholar Back to article
Oudiz R, Meyer C, Chin M, et al. Initial Data Report from “LARIAT”: A Phase 2 Study of Bardoxolone Methyl in PAH Patients on Stable Background Therapy. Chest. 2015 Oct; 148(4): 639A. doi: 10.1378/chest.2345856.
Open DOI Search in Google Scholar Back to article
ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; c2021. Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER (RANGER); 2017 Mar 1 [cited 2021 Apr 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03068130l.
Search in Google Scholar Back to article
ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; c2021. Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension – CATALYST; 2016 Jan 15 [cited 2021 Apr 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT02657356.
Search in Google Scholar Back to article
Zamanian RT, Hansmann G, Snook S, et al. Insulin resistance in pulmonary arterial hypertension. Eur Respir J. 2009 Feb; 33(2): 318–24. doi: 10.1183/09031936.00000508.
Search in Google Scholar Back to article
Agard C, Rolli-Derkinderen M, Dumas-de-La-Roque E, et al. Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension. Br J Pharmacol. 2009 Nov; 158(5): 1285–94. doi: 10.1111/j.1476-5381.2009.00445.x.
Search in Google Scholar Back to article
Dean A, Nilsen M, Loughlin L, Salt IP, MacLean MR. Metformin Reverses Development of Pulmonary Hypertension via Aromatase Inhibition. Hypertension. 2016 Aug; 68(2): 446–54. doi: 10.1161/HYPERTENSIONAHA.116.07353.
Search in Google Scholar Back to article
ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2021. Hormonal, Metabolic, and Signaling Interactions in PAH; 2020 Jun 16 [cited 2021 Jun 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT01884051.
Search in Google Scholar Back to article
Montani D, Chaumais MC, Guignabert C, et al. Targeted therapies in pulmonary arterial hypertension. 2014 Feb; 141(2): 172–91. doi: 10.1016/j.pharmthera.2013.10.002.
Search in Google Scholar Back to article
Hamidi SA, Lin RZ, Szema AM, et al. VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension. Respir Res. 2011 Oct 26; 12(1): 141. doi: 10.1186/1465-9921-12-141.
Search in Google Scholar Back to article
ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2021. Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH (VIP); 2021 Apr 27 [cited 2021 Jun 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT03556020.
Search in Google Scholar Back to article
Tofovic SP, Jackson EK. Estradiol Metabolism: Crossroads in Pulmonary Arterial Hypertension. Int J Mol Sci. 2019 Dec 23; 21(1): 116. doi: 10.3390/ijms21010116.
Open DOI Search in Google Scholar Back to article
ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2021. Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension (T3PAH); 2021 Feb 18 [cited 2021 Jun 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT03528902.
Search in Google Scholar Back to article
Kawut SM, Archer-Chicko CL, DeMichele A, et al. Anastrozole in Pulmonary Arterial Hypertension. A Randomized, Double-Blind, Placebo-controlled Trial. Am J Respir Crit Care Med. 2017 Feb 1; 195(3): 360–368. doi: 10.1164/rccm.201605-1024OC.
Search in Google Scholar Back to article
ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2021. Pulmonary Hypertension and Anastrozole Trial (PHANTOM); 2020 Aug 3 [cited 2021 Jun 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT03229499.
Search in Google Scholar Back to article
Bonnet S, Dumas-de-La-Roque E, Begueret H, et al.: Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension. Proc Natl Acad Sci U S A. 2003 Aug 5; 100(16): 9488–93. doi: 10.1073/pnas.1633724100.
Search in Google Scholar Back to article
ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2021. Effects of DHEA in Pulmonary Hypertension (EDIPHY); 2020 Oct 19 [cited 2021 Jun 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT03648385.
Search in Google Scholar Back to article
Houssaini A, Abid S, Mouraret N, et al. Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension. Am J Respir Cell Mol Biol. 2013 May; 48(5): 568–77. doi: 10.1165/rcmb.2012-0429OC.
Search in Google Scholar Back to article
ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2021. ABI-009, an mTOR Inhibitor, for Patients With Severe Pulmonary Arterial Hypertension; 2021 Feb 18 [cited 2021 Jun 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT02587325.
Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.14797/CBHS2234 | Journal eISSN: 1947-6108

Journal RSS Feed

Language: English

Page range: 29 - 37

Accepted on: Nov 18, 2020

Published on: Jul 1, 2021

Published by: Houston Methodist DeBakey Heart & Vascular Center

In partnership with: Paradigm Publishing Services

Keywords:

pulmonary arterial hypertension,

PAH pathways,

pulmonary hypertension

© 2021 Kanza N. Qaiser, Adriano R. Tonelli, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.

Volume 17 (2021): Issue 2